Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review. 2017

Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
University of British Columbia, Vancouver, and Arthritis Research Centre of Canada, Richmond, British Columbia, Canada.

Medication nonadherence has not been well characterized in systemic lupus erythematosus (SLE). Our objective was to a conduct a systematic review of the literature, examining the burden and determinants of medication nonadherence in SLE. We conducted a systematic search of Medline (1946-2015), Embase (1974-2015), and Web of Science (1900-2015) databases and selected original studies of SLE patients that evaluated nonadherence to SLE therapies as the primary study outcome. We extracted information on study design, sample size, length of followup, data sources, type of nonadherence problem examined, adherence measures and reported estimates, and determinants of adherence reported in multivariable analyses. After screening 4,111 titles, 11 studies met the inclusion criteria. Study sample sizes ranged from 32 to 246 patients, and studies were categorized according to data source: self-report (5), electronic monitoring devices (1), clinical records from rheumatology clinics (3), and refill information from pharmacy records (2). Overall, the percentage of nonadherent patients ranged from 43% to 75%, with studies consistently reporting that over half of patients are nonadherent. Studies also showed that up to 33% of patients discontinue therapy after 5 years. Determinants of nonadherence included having depression, rural residence, lower education level, and polypharmacy. Overall, synthesis of current evidence suggests that the burden of medication nonadherence is substantial in SLE. Findings highlight the importance of developing interventions to support adherence and improve outcomes among patients.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D055118 Medication Adherence Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency. Drug Adherence,Drug Compliance,Medication Compliance,Medication Nonadherence,Medication Non-Adherence,Medication Non-Compliance,Medication Noncompliance,Medication Persistence,Adherence, Drug,Adherence, Medication,Compliance, Drug,Compliance, Medication,Medication Non Adherence,Medication Non Compliance,Non-Adherence, Medication,Non-Compliance, Medication,Nonadherence, Medication,Noncompliance, Medication,Persistence, Medication
D057566 Self Report Method for obtaining information through verbal responses, written or oral, from subjects. Report, Self,Reports, Self,Self Reports

Related Publications

Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
August 2018, Lupus,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
January 2018, Patient preference and adherence,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
August 2021, Rheumatology international,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
February 2021, Lupus,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
April 2013, Lupus,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
January 1992, Clinical therapeutics,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
June 2011, Seminars in arthritis and rheumatism,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
January 2021, Journal of translational autoimmunity,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
July 2012, The Journal of clinical psychiatry,
Pavandeep Mehat, and Mohammad Atiquzzaman, and John M Esdaile, and Antonio AviÑa-Zubieta, and Mary A De Vera
October 2019, The Journal of rheumatology,
Copied contents to your clipboard!